| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer A de Gramont, A Figer, M Seymour, M Homerin, A Hmissi, J Cassidy, ... Journal of Clinical Oncology 41 (33), 5080-5089, 2023 | 5054 | 2023 |
| Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial T André, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, A Bonetti, ... J clin oncol 27 (19), 3109-3116, 2009 | 2716 | 2009 |
| Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial C Aschele, L Cionini, S Lonardi, C Pinto, S Cordio, G Rosati, S Artale, ... J Clin Oncol 29 (20), 2773-2780, 2011 | 940 | 2011 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 255 | 2020 |
| Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer … A Paccagnella, MG Ghi, L Loreggian, A Buffoli, H Koussis, CA Mione, ... Annals of oncology 21 (7), 1515-1522, 2010 | 216 | 2010 |
| Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of … MJ Piccart, JA Green, AJ Lacave, N Reed, I Vergote, P Benedetti-Panici, ... Journal of clinical oncology 18 (6), 1193-1202, 2000 | 196 | 2000 |
| Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years A De Gramont, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, ... Journal of Clinical Oncology 25 (18_suppl), 4007-4007, 2007 | 195 | 2007 |
| Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini, L Fornaro, ... Annals of Oncology 26 (4), 724-730, 2015 | 191 | 2015 |
| Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results … C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ... Annals of oncology 26 (6), 1188-1194, 2015 | 189 | 2015 |
| Platinum antitumor complexes: 50 years since Barnett Rosenberg’s discovery FM Muggia, A Bonetti, JD Hoeschele, M Rozencweig, SB Howell J. Clin. Oncol 33 (35), 4219-4226, 2015 | 187 | 2015 |
| Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial MG Ghi, A Paccagnella, D Ferrari, P Foa, D Alterio, C Codecà, F Nolè, ... Annals of Oncology 28 (9), 2206-2212, 2017 | 175 | 2017 |
| Ki‐67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis A Molino, R Micciolo, M Turazza, F Bonetti, Q Piubello, A Bonetti, R Nortilli, ... International journal of cancer 74 (4), 433-437, 1997 | 175 | 1997 |
| Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years A De Gramont, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, ... Journal of Clinical Oncology 23 (16_suppl), 3501-3501, 2005 | 168 | 2005 |
| Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma E Bajetta, M Di Bartolomeo, L Mariani, A Cassata, S Artale, S Frustaci, ... Cancer 100 (2), 279-287, 2004 | 162 | 2004 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 160 | 2022 |
| Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol P Perego, S Romanelli, N Carenini, I Magnani, R Leone, A Bonetti, ... Annals of Oncology 9 (4), 423-430, 1998 | 113 | 1998 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 107 | 2019 |
| Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer E Bajetta, I Floriani, M Di Bartolomeo, R Labianca, A Falcone, ... Annals of oncology 25 (7), 1373-1378, 2014 | 106 | 2014 |
| bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. A Bonetti, M Zaninelli, R Leone, GL Cetto, G Pelosi, S Biolo, A Menghi, ... Clinical cancer research: an official journal of the American Association …, 1998 | 101 | 1998 |
| Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods A Molino, R Micciolo, M Turazza, F Bonetti, Q Piubello, A Corgnati, ... Breast cancer research and treatment 45, 241-249, 1997 | 92 | 1997 |
